Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Invested Capital (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Invested Capital data on record, last reported at $333.3 million in Q1 2026.

  • On a quarterly basis, Invested Capital rose 45.87% to $333.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $333.3 million, a 45.87% increase, with the full-year FY2025 number at $349.0 million, up 43.6% from a year prior.
  • Invested Capital reached $333.3 million in Q1 2026 per FULC's latest filing, down from $349.0 million in the prior quarter.
  • Over the last five years, Invested Capital for FULC hit a ceiling of $349.0 million in Q4 2025 and a floor of $160.8 million in Q2 2022.
  • A 5-year average of $243.8 million and a median of $235.2 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: surged 71.33% in 2023, then dropped 27.9% in 2024.
  • Tracing FULC's Invested Capital over 5 years: stood at $198.9 million in 2022, then grew by 18.22% to $235.2 million in 2023, then increased by 3.33% to $243.0 million in 2024, then soared by 43.6% to $349.0 million in 2025, then dropped by 4.5% to $333.3 million in 2026.
  • Business Quant data shows Invested Capital for FULC at $333.3 million in Q1 2026, $349.0 million in Q4 2025, and $198.4 million in Q3 2025.